There is little doubt that medication-assisted treatment (MAT) approaches are effective in for SUD in general, and opioid use disorder (OUD) in particular. But the evidence-based, MAT utilization lags. Did you know: any clinician with a current DEA registration that includes Schedule III authority can now prescribe buprenorphine, the most effective, FDA-approved treatment for opioid use disorder? And the maximum number of consumers with substance use disorder (SUD) who can be treated by a provider has increased. However, a year after the changes in regulation to expand access to life-saving medications, there has not been a meaningful increase in buprenorphine use.